Cellectar Biosciences Inc...

0.31
-0.00 (-0.77%)
At close: Apr 24, 2025, 3:59 PM
0.31
0.55%
After-hours: Apr 24, 2025, 05:59 PM EDT
-0.77%
Bid 0.29
Market Cap 14.36M
Revenue (ttm) n/a
Net Income (ttm) -39.52M
EPS (ttm) -1.4
PE Ratio (ttm) -0.22
Forward PE -0.43
Analyst Buy
Ask 0.31
Volume 344,844
Avg. Volume (20D) 1,140,301
Open 0.30
Previous Close 0.31
Day's Range 0.30 - 0.31
52-Week Range 0.22 - 3.51
Beta 0.67

About CLRB

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients;...

Industry Biotechnology
Sector Healthcare
IPO Date Nov 10, 2005
Employees 11
Stock Exchange NASDAQ
Ticker Symbol CLRB
Full Company Profile

Analyst Forecast

According to 2 analyst ratings, the average rating for CLRB stock is "Buy." The 12-month stock price forecast is $28, which is an increase of 8885.88% from the latest price.

Stock Forecasts
4 months ago
-76.16%
Cellectar Biosciences shares are trading lower aft... Unlock content with Pro Subscription
9 months ago
-18.54%
Cellectar Biosciences shares are trading lower. The company announced results from its CLOVER WaM pivotal study evaluating iopofosine I 131.